AR074240A1 - Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci - Google Patents

Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci

Info

Publication number
AR074240A1
AR074240A1 ARP090104627A ARP090104627A AR074240A1 AR 074240 A1 AR074240 A1 AR 074240A1 AR P090104627 A ARP090104627 A AR P090104627A AR P090104627 A ARP090104627 A AR P090104627A AR 074240 A1 AR074240 A1 AR 074240A1
Authority
AR
Argentina
Prior art keywords
methyl
imidazo
chloro
prepare
compound
Prior art date
Application number
ARP090104627A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074240(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR074240A1 publication Critical patent/AR074240A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP090104627A 2008-12-16 2009-12-01 Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci AR074240A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16

Publications (1)

Publication Number Publication Date
AR074240A1 true AR074240A1 (es) 2011-01-05

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104627A AR074240A1 (es) 2008-12-16 2009-12-01 Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci

Country Status (38)

Country Link
US (2) US7897600B2 (https=)
EP (1) EP2379557B1 (https=)
JP (1) JP5509217B2 (https=)
KR (1) KR101300458B1 (https=)
CN (1) CN102232075B (https=)
AR (1) AR074240A1 (https=)
AU (1) AU2009330503B2 (https=)
BR (1) BRPI0923048A2 (https=)
CA (1) CA2744714C (https=)
CL (1) CL2011001445A1 (https=)
CO (1) CO6331442A2 (https=)
CR (1) CR20110341A (https=)
CY (1) CY1113637T1 (https=)
DK (1) DK2379557T3 (https=)
DO (1) DOP2011000190A (https=)
EA (1) EA019554B1 (https=)
EC (1) ECSP11011132A (https=)
ES (1) ES2396617T3 (https=)
HN (1) HN2011001697A (https=)
HR (1) HRP20120918T1 (https=)
IL (1) IL213065A0 (https=)
JO (1) JO2833B1 (https=)
MA (1) MA32900B1 (https=)
MX (1) MX2011006441A (https=)
MY (1) MY158691A (https=)
NZ (1) NZ592641A (https=)
PA (1) PA8851101A1 (https=)
PE (1) PE20110549A1 (https=)
PL (1) PL2379557T3 (https=)
PT (1) PT2379557E (https=)
SG (1) SG172202A1 (https=)
SI (1) SI2379557T1 (https=)
SV (1) SV2011003949A (https=)
TN (1) TN2011000292A1 (https=)
TW (1) TWI440640B (https=)
UA (1) UA104743C2 (https=)
WO (1) WO2010074947A1 (https=)
ZA (1) ZA201103942B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
BR112013032360A2 (pt) * 2011-06-15 2017-06-13 Life And Brain Gmbh compostos inibidores de glioblastoma e seu uso
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
MA40596B1 (fr) 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
US20170239351A1 (en) 2014-08-11 2017-08-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
EP3541817B1 (en) * 2016-11-17 2020-12-23 Bristol-Myers Squibb Company Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ526472A (en) 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
CA2467718C (en) 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CA2598076A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
PT1853588E (pt) 2005-02-16 2008-08-25 Astrazeneca Ab Compostos químicos
PL1899329T3 (pl) * 2005-07-01 2012-03-30 Irm Llc Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
TWI333953B (en) * 2005-10-06 2010-12-01 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
CN101321760A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
KR20080080584A (ko) * 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
CN101522682A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
CA2686485A1 (en) 2007-05-23 2008-11-27 Pharmacopeia, Llc Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Also Published As

Publication number Publication date
AU2009330503A1 (en) 2010-07-01
DK2379557T3 (da) 2012-12-17
UA104743C2 (ru) 2014-03-11
AU2009330503B2 (en) 2012-06-07
CN102232075B (zh) 2013-12-11
CN102232075A (zh) 2011-11-02
SG172202A1 (en) 2011-07-28
TN2011000292A1 (en) 2012-12-17
HK1160109A1 (en) 2012-08-10
US20100152181A1 (en) 2010-06-17
PA8851101A1 (es) 2010-07-27
CY1113637T1 (el) 2016-06-22
MY158691A (en) 2016-10-31
US20100286139A1 (en) 2010-11-11
PL2379557T3 (pl) 2013-03-29
JP2012512158A (ja) 2012-05-31
ES2396617T3 (es) 2013-02-22
US7897600B2 (en) 2011-03-01
NZ592641A (en) 2013-01-25
JO2833B1 (en) 2014-09-15
TWI440640B (zh) 2014-06-11
IL213065A0 (en) 2011-07-31
JP5509217B2 (ja) 2014-06-04
BRPI0923048A2 (pt) 2018-09-25
CR20110341A (es) 2011-07-13
CA2744714C (en) 2013-06-25
ECSP11011132A (es) 2011-07-29
CL2011001445A1 (es) 2011-11-11
KR20110084993A (ko) 2011-07-26
PT2379557E (pt) 2013-01-14
KR101300458B1 (ko) 2013-08-30
MX2011006441A (es) 2011-07-19
SI2379557T1 (sl) 2013-02-28
EP2379557B1 (en) 2012-10-31
CA2744714A1 (en) 2010-07-01
ZA201103942B (en) 2012-08-29
EP2379557A1 (en) 2011-10-26
WO2010074947A1 (en) 2010-07-01
TW201024301A (en) 2010-07-01
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
HRP20120918T1 (hr) 2012-12-31
PE20110549A1 (es) 2011-08-04
EA019554B1 (ru) 2014-04-30
EA201170831A1 (ru) 2011-12-30
CO6331442A2 (es) 2011-10-20
DOP2011000190A (es) 2011-07-31
HN2011001697A (es) 2013-11-26

Similar Documents

Publication Publication Date Title
AR074240A1 (es) Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
AR085183A1 (es) Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
CU20130069A7 (es) Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis
CL2008003393A1 (es) Compuestos derivados de imidazo[1,2-a]piridina, moduladores alostericos de los receptores de mglur2; composicion farmaceutica que comprende a dichos compuestos; y su uso en la preparacion de medicamentos para tratar trastornos del sistema nervioso central.
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
CL2007001554A1 (es) Compuestos derivados de pirido [3,2-e]pirazinas;inhibidoras de pde10;procedimiento de preparacion;composicion farmaceutica que comprende; kit farmaceutico; uso para preparar de un medicamento para tratar o prevenir trastornos asociados a la hiperactividad de pde10 y/o trastornos en los que inhibir la pde10 es de valor.
MX2010002115A (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
EP4249076A3 (en) (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2014144130A3 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
CL2013001677A1 (es) Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia.
SV2009003288A (es) Derivados de 2, 3-dihidroimidazo [1,2-c] quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
CL2012001714A1 (es) Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras.
BR112016003229A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2011157416A3 (de) Transdermale verabreichung von memantin
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion

Legal Events

Date Code Title Description
FB Suspension of granting procedure